BioSpace News Archive

Kymera to receive $150 million upfront with more than $2 billion in potential milestones plus royalty payments

Platform based on groundbreaking research from the laboratory of Professor Edgar Engleman, MD, at Stanford University indicating that myeloid immune cell dysfunction underlies a variety of nervous system disorders

The JBR Clinical Research surgical center emphasizes its dedication to safety and quality with the receipt of accreditation from the not-for-profit American Association for Accreditation of Ambulatory Surgery Facilities (AAAASF)

New funding will drive advancement of a global therapeutic portfolio in oncology and immunology, including monoclonal antibodies for COVID-19 therapeutics and diagnostics

Neovasc, Inc. (“Neovasc” or the “Company”) ( NASDAQ , TSX : NVCN), announced today that it has been informed by the U.S. Food and Drug Administration (FDA) that the Circulatory System Devices Panel of the Medical Devices Advisory Committee will review the premarket approval application (PMA) for the Neovasc Reducer™ device (“Reducer”) at its October 27, 2020 meeting. Neovasc is seeking approval for Reducer in t

MediPharm Labs Corp ., (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, is pleased to announce that MediPharm Labs’ management will participate in the CBD BioPharma Virtual Investor Conference on Thursday, July 9 th . The audio webcast presentation will begin at 11:30am Eastern Time. Pa

Tris Pharma, Inc. (“Tris”), a specialty pharmaceutical company with a robust portfolio of FDA-approved products for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and related disorders, and KYE Pharmaceuticals Inc. (“KYE”), a private company headquartered in Mississauga, Ontario a

Optibrium’s StarDrop™ drug discovery software inspires the next generation of high-school students in their challenge to target COVID-19

Absolute Antibody Ltd., an industry-leading provider of recombinant antibody products and services, announced a partnership with University of Zurich to offer synthetic nanobodies against the receptor binding domain of SARS-CoV-2, the coronavirus that causes COVID-19.

Global Biopharmaceutical Contract Development and Manufacturing Organization AGC Biologics is partnering with clinical-stage biotech company Molecular Partners AG to develop a new class of custom-built protein therapeutics known as DARPin®.